arrow
P

Philip M. Carlucci

nyu langone health
H指数:24
被引数:2,815

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment

狼疮性肾炎的血清可溶性介质特征:组织学特征及治疗反应

2025-12-010
OAAI
Prospective Evaluation of High Titer Autoantibodies and Fetal Home Monitoring in the Detection of Atrioventricular Block Among Anti-SSA/Ro Pregnancies
2023-11-1013
PRE
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network
2021-08-134
OAAI
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
2021-06-07128
OAAI
Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus
2020-10-2851
OAAI
Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019
2020-09-09146
OAAI
Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus

转录组,表观遗传和功能分析暗示嗜中性粒细胞多样性在系统性红斑狼疮的发病机理中

2019-11-21174
OAAI
Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa
2019-09-04103
OAAI
Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus
2019-05-0849
OAAI
Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus
2018-04-19150
OA